Low-dose pegylated recombinant human granulocyte-colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open-label, randomized, non-inferiority trial.

MLA

Yang, Sheng, et al. “Low-Dose Pegylated Recombinant Human Granulocyte-Colony Stimulating Factor as Hematopoietic Support for Adjuvant Chemotherapy in Chinese Patients with Breast Cancer: An Open-Label, Randomized, Non-Inferiority Trial.” British Journal of Clinical Pharmacology, vol. 90, no. 10, Oct. 2024, pp. 2621–29. EBSCOhost, https://doi.org/10.1111/bcp.16151.

APA

Yang, S., Chen, S.-S., Zhang, C.-G., Zhou, Y.-L., Xiu, M., & Zhang, P. (2024). Low-dose pegylated recombinant human granulocyte-colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open-label, randomized, non-inferiority trial. British Journal of Clinical Pharmacology, 90(10), 2621–2629. https://doi.org/10.1111/bcp.16151

Chicago

Yang, Sheng, Shan-Shan Chen, Chang-Gong Zhang, Ying-Lei Zhou, Meng Xiu, and Pin Zhang. 2024. “Low-Dose Pegylated Recombinant Human Granulocyte-Colony Stimulating Factor as Hematopoietic Support for Adjuvant Chemotherapy in Chinese Patients with Breast Cancer: An Open-Label, Randomized, Non-Inferiority Trial.” British Journal of Clinical Pharmacology 90 (10): 2621–29. doi:10.1111/bcp.16151.